ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
HER2-low breast cancer has recently emerged as a targetable subset of breast tumors, based on the evidence from clinical trials of novel anti-HER2 antibody-drug conjugates. This evolution has raised several biological and clinical questions, warranting the establishment of consensus to optimally treat patients with HER2-low breast tumors. Between 2022 and 2023, the European Society for Medical Oncology (ESMO) held a virtual consensus-building process focused on HER2-low breast cancer. The consensus included a multidisciplinary panel of 32 leading experts in the management of breast cancer from 9 different countries. The aim of the consensus was to develop statements on topics that are not covered in detail in the current ESMO Clinical Practice Guideline. The main topics identified for discussion were: (i) biology of HER2-low breast cancer; (ii) pathologic diagnosis of HER2-low breast cancer; (iii) clinical management of HER2-low metastatic breast cancer and (iv) clinical trial design for HER2-low breast cancer. The expert panel was divided into four working groups to address questions relating to one of the four topics outlined above. A review of the relevant scientific literature was conducted in advance. Consensus statements were developed by the working groups and then presented to the entire panel for further discussion and amendment before voting. This manuscript presents the developed statements, including findings from the expert panel discussions, expert opinion and a summary of evidence supporting each statement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Self-citationTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Self-citationWolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8738 · Cited by 2,435
Self-citationLoibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Self-citationLoibl, S., & Gianni, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32417-5 · Cited by 1,116
Self-citationHER2-Low Breast Cancer: Pathological and Clinical Landscape
Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 791
Self-citationModi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Self-citationOgitani, Y., Hagihara, K., Oitate, M., Naito, H., & Agatsuma, T. (2016) · Cancer Science · doi:10.1111/cas.12966 · Cited by 751
Hurvitz, S. A., Hegg, R., Chung, W.-P., Im, S.-A., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., Hamilton, E., Madhusudan, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02420-5 · Cited by 687
Self-citationClinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Schettini, F., Chic, N., Brasó-Maristany, F., Paré, L., Pascual, T., Conte, B., Martínez-Sáez, O., Adamo, B., Vidal, M., Barnadas, E., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-020-00208-2 · Cited by 670
Denkert, C., Seither, F., Schneeweiss, A., Link, T., Blohmer, J.-U., Just, M., Wimberger, P., Forberger, A., Tesch, H., Jackisch, C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00301-6 · Cited by 552
Self-citationBanerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
The Distinctive Nature of HER2-Positive Breast Cancers
Burstein, H. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058197 · Cited by 541
Self-citationFehrenbacher, L., Cecchini, R. S., Geyer Jr, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J.-F., Provencher, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01455 · Cited by 404
André, F., Hee Park, Y., Kim, S.-B., Takano, T., Im, S.-A., Borges, G., Lima, J. P., Aksoy, S., Gavila Gregori, J., De Laurentiis, M., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00725-0 · Cited by 379
Self-citationExamination of Low ERBB2 Protein Expression in Breast Cancer Tissue
Fernandez, A. I., Liu, M., Bellizzi, A. M., Brock, J. E., Fadare, O., Hanley, K. Z., Harigopal, M., Jorns, J. M., Kuba, M. G., Ly, A., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.7239 · Cited by 344
Powell, C. A., Modi, S., Iwata, H., Takahashi, S., Smit, E. F., Siena, S., Chang, D.-Y., Macpherson, E., Qin, A., Singh, J., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100554 · Cited by 270
Self-citationHER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., & de Azambuja, E. (2021) · Cancers · doi:10.3390/cancers13112824 · Cited by 267
Gianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P.-L., Cameron, D. A., Miles, D., Salvagni, S., Wardley, A., Goeminne, J.-C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1661 · Cited by 262
Self-citationEvolution of HER2-low expression from primary to recurrent breast cancer
Miglietta, F., Griguolo, G., Bottosso, M., Giarratano, T., Lo Mele, M., Fassan, M., Cacciatore, M., Genovesi, E., De Bartolo, D., Vernaci, G., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00343-4 · Cited by 225
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer
Tarantino, P., Jin, Q., Tayob, N., Jeselsohn, R. M., Schnitt, S. J., Vincuilla, J., Parker, T., Tyekucheva, S., Li, T., Lin, N. U., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.2286 · Cited by 205
Self-citationHorisawa, N., Adachi, Y., Takatsuka, D., Nozawa, K., Endo, Y., Ozaki, Y., Sugino, K., Kataoka, A., Kotani, H., Yoshimura, A., et al. (2022) · Breast Cancer · doi:10.1007/s12282-021-01303-3 · Cited by 196
Evolution of low HER2 expression between early and advanced-stage breast cancer
Tarantino, P., Gandini, S., Nicolò, E., Trillo, P., Giugliano, F., Zagami, P., Vivanet, G., Bellerba, F., Trapani, D., Marra, A., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2021.12.022 · Cited by 187
Self-citationSwain, S. M., Nishino, M., Lancaster, L. H., Li, B. T., Nicholson, A. G., Bartholmai, B. J., Naidoo, J., Schumacher-Wulf, E., Shitara, K., Tsurutani, J., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102378 · Cited by 185
Current and Future Management of HER2-Positive Metastatic Breast Cancer
Martínez-Sáez, O., & Prat, A. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00172 · Cited by 183
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review
Tarantino, P., Modi, S., Tolaney, S. M., Cortés, J., Hamilton, E. P., Kim, S.-B., Toi, M., Andrè, F., & Curigliano, G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.3595 · Cited by 172
Self-citationWon, H. S., Ahn, J., Kim, Y., Kim, J. S., Song, J.-Y., Kim, H.-K., Lee, J., Park, H. K., & Kim, Y.-S. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01519-x · Cited by 171
HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer
de Moura Leite, L., Cesca, M. G., Tavares, M. C., Santana, D. M., Saldanha, E. F., Guimarães, P. T., Sá, D. D. S., Simões, M. F. E., Viana, R. L., Rocha, F. G., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06365-7 · Cited by 168
Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
Moutafi, M. K., Robbins, C. T., Yaghoobi, V., Fernandez, A. I., Martínez-Morilla, S., Xirou, V., Bai, Y., Song, Y., Gaule, P., Krueger, J. S., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00804-9 · Cited by 156
Peiffer, D. S., Zhao, F., Chen, N., Hahn, O. M., Nanda, R., Olopade, O. I., Huo, D., & Howard, F. M. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.7476 · Cited by 149
Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry
Gampenrieder, S. P., Rinnerthaler, G., Tinchon, C., Petzer, A. L., Balić, M., Heibl, S., Schmitt, C. A., Zabernigg, A. F., Egle, D., Sandholzer, M., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01492-x · Cited by 147
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer
Mutai, R., Barkan, T., Moore, A., Sarfaty, M., Shochat, T., Yerushalmi, R., Stemmer, S. M., & Goldvaser, H. (2021) · The Breast · doi:10.1016/j.breast.2021.08.016 · Cited by 140
Reisenbichler, E. S., Han, G., Bellizzi, A., Bossuyt, V., Brock, J., Cole, K., Fadare, O., Hameed, O., Hanley, K., Harrison, B. T., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0544-x · Cited by 133
Tan, R. S. Y. C., Ong, W. S., Lee, K.-H., Lim, A. H., Park, S., Park, Y. H., Lin, C., Lu, Y., Ono, M., Ueno, T., et al. (2022) · BMC Medicine · doi:10.1186/s12916-022-02284-6 · Cited by 132
Khan, A. R., Khan, S., Zimmerman, V. A., Baddour, L. M., & Tleyjeh, I. M. (2010) · Clinical Infectious Diseases · doi:10.1086/656735 · Cited by 126
Zhang, H., Katerji, H., Turner, B. M., Audeh, W., & Hicks, D. G. (2022) · Modern Pathology · doi:10.1038/s41379-022-01019-5 · Cited by 123
Jacot, W., Maran-Gonzalez, A., Massol, O., Sorbs, C., Mollévi, C., Guiu, S., Boissière‐Michot, F., & Ramos, J. (2021) · Cancers · doi:10.3390/cancers13236059 · Cited by 118
Self-citationMiglietta, F., Griguolo, G., Bottosso, M., Giarratano, T., Mele, M. L., Fassan, M., Cacciatore, M., Genovesi, E., Bartolo, D. D., Vernaci, G. M., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00434-w · Cited by 118
Schmid, P., Im, S., Armstrong, A. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.1023 · Cited by 114
Self-citationSchettini, F., Giudici, F., Giuliano, M., Cristofanilli, M., Arpino, G., Mastro, L. D., Puglisi, F., Placido, S. D., Paris, I., Placido, P. D., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa071 · Cited by 111
Wang, J., Liu, Y., Zhang, Q., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.1022 · Cited by 104
Wu, S., Yue, M., Zhang, J., Li, X., Li, Z., Zhang, H., Wang, X., Han, X., Cai, L., Shang, J., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2022.100054 · Cited by 101
Takegawa, N., Tsurutani, J., Kawakami, H., Yonesaka, K., Kato, R., Haratani, K., Hayashi, H., Takeda, M., Nonagase, Y., Maenishi, O., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32408 · Cited by 90
Rüschoff, J., Friedrich, M., Nagelmeier, I., Kirchner, M., Andresen, L., Salomon, K., Portier, B. P., Sredni, S. T., Schildhaus, H., Jasani, B., et al. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03378-5 · Cited by 76
Self-citationNavigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons
Tarantino, P., Curigliano, G., & Tolaney, S. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0703 · Cited by 75
Self-citationKaufman, P. A., Bloom, K. J., Burris, H. A., Gralow, J. R., Mayer, M., Pegram, M. D., Rugo, H. S., Swain, S. M., Yardley, D. A., Chau, M., et al. (2014) · Cancer · doi:10.1002/cncr.28710 · Cited by 68
HER2-low breast cancer could be associated with an increased risk of brain metastasis
Güven, D. C., Kaya, M. B., Fedai, B., Ozden, M., Yıldırım, H. Ç., Kösemehmetoğlu, K., Kertmen, N., Dızdar, Ö., Üner, A., & Aksoy, S. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-02049-w · Cited by 54
How current assay approval policies are leading to unintended imprecision medicine
Salgado, R., Bellizzi, A. M., Rimm, D. L., Bartlett, J. M. S., Nielsen, T. O., Moch, H., Lænkholm, A., Quinn, C., Cserni, G., da Cunha, I. W., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30592-1 · Cited by 49
Self-citationMosele, M. F., Lusque, A., Dieras, V. C., Deluche, É., Ducoulombier, A., Pistilli, B., Bachelot, T., Viret, F., Lévy, C., Signolle, N., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.03.277 · Cited by 49
Self-citationManagement of Early-Stage Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Pernas, S., & Tolaney, S. M. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00020 · Cited by 40
Self-citationCarlino, F., Diana, A., Ventriglia, A., Piccolo, A., Mocerino, C., Riccardi, F., Bilancia, D., Giotta, F., Antoniol, G., Famiglietti, V., et al. (2022) · Cancers · doi:10.3390/cancers14204981 · Cited by 38
Jiang, Z., Sun, T., Wang, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.1102 · Cited by 37
Cosimo, S. D., Rocca, E. L., Ljevar, S., Santis, M. C. D., Bini, M., Cappelletti, V., Valenti, M., Baili, P., de Braud, F., Folli, S., et al. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.996434 · Cited by 35
Self-citationBianchini, G., Arpino, G., Biganzoli, L., Lonardi, S., Puglisi, F., Santini, D., Lambertini, M., & Pappagallo, G. L. (2022) · Cancers · doi:10.3390/cancers14041022 · Cited by 30
Schmid, P., Wysocki, P. J., Park, Y. H., et al. (2023) · Cancer Research · doi:10.1158/1538-7445.sabcs22-pd11-08 · Cited by 30
Self-citationSchmid, P., Cortés, J., Marmé, F., Rugo, H. S., Tolaney, S. M., Oliveira, M., Loirat, D., Jhaveri, K. L., Yoon, O. K., Motwani, M., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.07.253 · Cited by 26
Self-citationGenomic and transcriptomic landscape of HER2-low breast cancer
Bansal, R., Adeyelu, T. T., Elliott, A., Walker, P., Bustos, M. A., Rodríguez, E., Accordino, M. K., Meisel, J. L., Gatti-Mays, M. E., Hsu, E., et al. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07495-4 · Cited by 14
Mastering the Use of Novel Anti-HER2 Treatment Options
Tarantino, P., Trapani, D., & Curigliano, G. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00216 · Cited by 12
Self-citationNilsson, M. B., Poteete, A., Udagawa, H., Yu, X., He, J., Le, X., & Heymach, J. V. (2023) · Cancer Research · doi:10.1158/1538-7445.am2023-383 · Cited by 10
Cited by
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
Bardia, A., Hu, X., Dent, R., Yonemori, K., Barrios, C. H., O’Shaughnessy, J. A., Wildiers, H., Pierga, J.-Y., Zhang, Q., Saura, C., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2407086 · Cited by 485
Self-citationTrastuzumab deruxtecan in breast cancer
Martín, M., Pandiella, A., Vargas-Castrillón, E., Díaz-Rodríguez, E., Iglesias-Hernangómez, T., Martínez Cano, C., Fernández-Cuesta, I., Winkow, E., & Perelló, M. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104355 · Cited by 103
Metadata
- Authors
- Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., Denkert, C., Diéras, V., Jacot, W., Koutras, A. K., Lebeau, A., Loibl, S., Modi, S., Mosele, M. F., Provenzano, E., Pruneri, G., Reis-Filho, J. S., Rojo, F., Salgado, R., Schmid, P., Schnitt, S. J., Tolaney, S. M., Trapani, D., Vincent-Salomon, A., Wolff, A. C., Pentheroudakis, G., André, F., & Curigliano, G.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2023-08
- Volume
- 34
- Issue
- 8
- Pages
- 645-659
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4378978327
- Cited by
- 312
- References
- 60
- FWCI
- 32.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.